论文部分内容阅读
目的 观察艾拉莫德片联合雷公藤多苷片治疗活动期老年类风湿关节炎(RA)的临床疗效及安全性.方法 将90例活动期老年RA患者随机分为对照组和试验组,每组45例.对照组予以雷公藤多苷每次20 mg,tid,口服;试验组在对照组治疗的基础上,予以艾拉莫德每次25 mg,bid,口服. 2组患者均治疗24周.比较2组患者的临床疗效,红细胞沉降率(ESR)、C反应蛋白(CRP)、类风湿因子(RF)的水平,以及药物不良反应的发生情况.结果 治疗后,试验组和对照组的ACR20有效率分别为86.67%(39 例/45 例)和46.67%(21 例/45例),ACR50有效率分别为68.89%(31 例/45 例)和31.11%(14 例/45 例), ACR70有效率分别为24.44%(11例/45例)和6.67%(3例/45例),差异均有统计学意义(均 P <0.05 ).治疗后,试验组和对照组的 ESR 分别为(16.42 ±9.87 )和( 23.36 ±10.16 ) mm· h-1, CRP 分别为( 6.59 ±4.05 )和(11.42 ±6.64) mg· L-1, RF 分别为( 50.06 ±15.49 )和( 61.34 ±22.30 ) U· mL-1,差异均有统计学意义(均P0.05).结论 艾拉莫德片联合雷公藤多苷片治疗活动期老年RA患者的临床疗效明显优于雷公藤多苷片单药治疗,且不增加药物不良反应的发生率.“,”Objective To observe the clinical efficacy and safety of igu-ratimod tablets combined with tripterysium glycosides tablets in the treat-ment of elderly patients with active rheumatoid arthritis ( RA).Methods A total of 90 elderly patients with active RA were randomly divided in-to control and treatment groups with 45 cases per group.Control group was given tripterysium glycosides 20 mg per time, tid, orally.Treatment group was given iguratimod 25 mg per time, bid, orally, on the basis of control group.Two groups were treated for 24 weeks.The clinical effica-cy, the levels of erythrocyte sedimentation rate (ESR), C-reactive pro-tein(CRP) and rheumatoid factor(RF), and adverse drug reactions were compared between two groups.Results Compared with treatment group and control groups after treatment , the effective rates of ACR20 were 86.67%(39 cases /45 cases) and 46.67%(21 cases /45 cases), the effective rates of ACR50 were 68.89%(31 cases /45 cases) and 31.11%(14 cases /45 cases), the effective rates of ACR70 were 24.44%(11 cases /45 cases) and 6.67%(3 ca-ses /45 cases), the differences were statistically significant (all P<0.05).After treatment, the main indexes of treatment and control groups were compared : ESR were (16.42 ±9.87 ) and (23.36 ±10.16 ) mm· h-1, CRP were (6.59 ±4.05) and (11.42 ±6.64)mg· L-1, RF were (50.06 ±15.49) and (61.34 ±22.30)U· mL-1, the diffe-rences were statistically significant ( all P0.05 ).Conclusion Iguratimod tablets com-bined with tripterysium glycosides tablets have a definitive clinical efficacy in the treatment of elderly patients with ac -tive RA, which is better than tripterysium glycosides alone , without increasing the incidence of adverse drug reactions .